--Must See--

Bioinformatics Summer Internship 2024 With Hands-On-Training + Project / Dissertation - 30 Days, 3 Months & 6 Months Duration

Oxford Biotech Develops Blood Biopsy That Identifies Breast Cancer

UK-based Oxford BioDynamics is a biotech firm focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry. The company has now announced successful diagnosis of breast cancer in a Caucasian cohort of patients using its proprietary technology platform EpiSwitch.

After what the company called this “first milestone”, it plans to expand the analysis across the cohort of 136 patients to focus on those with a family history of breast cancer and high risk of genetic predisposition.

The next step for Oxford BioDynamics is to investigate patients’ family histories of breast cancer to analyze genetic predisposition for breast cancer.

We are very pleased with the latest results delivered by our EpiSwitch technology in which we have been successful in diagnosing and staging breast cancer in a Caucasian patient cohort

“, Oxford BioDynamics Chief Executive Officer Christian Hoyer Millar said. “We are delighted to be working with MCMCC and extremely grateful for the excellent quality of the clinical cohort provided for our study.”

We are looking forward to the next stage of our collaboration,” Millar added, “as we believe our technology can deliver stratification insights that will assist oncologists and their patients for better, more informed clinical decisions in the difficult cases that involve a family history or high genetic predisposition for breast cancer.

Millar said the company was “excited” by this latest development and the “benefits” in patient care it would be able to offer.

In search of the perfect burger. Serial eater. In her spare time, practises her "Vader Voice". Passionate about dance. Real Weird.